Functional differences between PD-1⁺ and PD-1⁻CD4⁺ effector T cells in healthy donors and patients with glioblastoma multiforme
mmune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been highly successful in the treatment of cancer. While PD-1 expression has been widely investigated, its role in CD4⁺ effector T cells in the setting of health and cancer remains unclear, particularly in the setting...
| Main Authors: | , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Public Library of Science
2017
|
| Online Access: | http://hdl.handle.net/1721.1/111673 https://orcid.org/0000-0002-5962-9570 https://orcid.org/0000-0003-0921-3144 |